Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-08-19

Clinical Trial Update: 12-week Efficacy of Indacaterol [Phase 3]

View source ↗

Summary

Novartis completed a Phase 3 trial assessing the 12-week efficacy of indacaterol in chronic obstructive pulmonary disease, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Indacaterol (Arcapta Neohaler) (Indacaterol)

Snippet

Sponsor: Novartis | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2011-08-19